IMNN shares implications of trial pace as company targets early 2027 data readout for OVATION 2 study.
Imunon disclosed an enrollment rate of 0.5 patients per site per month for its OVATION 3 trial during its Q2 2026 earnings call. The company highlighted progress in validating its lead asset, IMNN-001, and the TheraPlas platform as key milestones for the quarter.
Management previously outlined plans to present data from the OVATION 2 study in early 2027. The current enrollment pace provides context for trial timelines and potential regulatory pathways. No prior consensus estimates for enrollment rates were publicly disclosed.
The update follows a period of focused execution, with leadership emphasizing validation of its clinical programs as a critical step forward.